11085 related articles for article (PubMed ID: 10404438)
1. The modulatory impact of recombinant human interleukin-6 on the immune system of cancer patients.
Nieken J; Mulder NH; Pietens J; Limburg PC; de Leij L; de Vries EG
J Immunother; 1999 Jul; 22(4):363-70. PubMed ID: 10404438
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.
Nieken J; Mulder NH; Buter J; Vellenga E; Limburg PC; Piers DA; de Vries EG
Blood; 1995 Aug; 86(3):900-5. PubMed ID: 7542502
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
4. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
6. Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
Hayat K; Rodgers S; Bruce L; Rees RC; Chapman K; Reeder S; Dorreen MS; Sheridan E; Sreenivasan T; Hancock BW
Eur J Cancer; 1991; 27(8):1009-14. PubMed ID: 1832884
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.
van Gameren MM; Willemse PH; Mulder NH; Limburg PC; Groen HJ; Vellenga E; de Vries EG
Blood; 1994 Sep; 84(5):1434-41. PubMed ID: 8068939
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.
Stouthard JM; Goey H; de Vries EG; de Mulder PH; Groenewegen A; Pronk L; Stoter G; Sauerwein HP; Bakker PJ; Veenhof CH
Br J Cancer; 1996 Mar; 73(6):789-93. PubMed ID: 8611381
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
Schuler M; Peschel C; Schneller F; Fichtner J; Färber L; Huber C; Aulitzky WE
J Interferon Cytokine Res; 1996 Nov; 16(11):903-10. PubMed ID: 8938565
[TBL] [Abstract][Full Text] [Related]
11. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profile during high-dose rhG-CSF therapy in severe congenital neutropenia.
Shitara T; Yugami S; Ijima H; Sotomatu M; Kuroume T
Am J Hematol; 1994 Jan; 45(1):58-62. PubMed ID: 7504401
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes.
Hennemann B; Rehm A; Kottke A; Meidenbauer N; Andreesen R
J Immunother; 1997 Sep; 20(5):365-71. PubMed ID: 9336743
[TBL] [Abstract][Full Text] [Related]
14. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2.
Engelhardt M; Wirth K; Mertelsmann R; Lindemann A; Brennscheidt U
Eur J Cancer; 1997 Jun; 33(7):1050-4. PubMed ID: 9376186
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects.
Banks RE; Forbes MA; Patel PM; Storr M; Hallam S; Clarke D; Novick D; Ingham E; Bowmer C; Southgate J; Trejdosiewicz LK; Illingworth J; Perren TJ; Selby PJ
Cytokine; 2000 Apr; 12(4):388-96. PubMed ID: 10805221
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Urol Int; 1998; 61(4):215-9. PubMed ID: 10364752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
